Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Update

Intensity Therapeutics Inc. (NASDAQ:INTS) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 31,298 shares, a decline of 36.0% from the August 31st total of 48,911 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average daily volume of 12,048 shares, the short-interest ratio is presently 2.6 days.

Intensity Therapeutics Stock Up 7.2%

NASDAQ:INTS opened at $3.44 on Friday. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The stock has a market cap of $11.21 million, a price-to-earnings ratio of -0.96 and a beta of 2.81. The stock has a 50-day moving average price of $4.11 and a two-hundred day moving average price of $4.60. Intensity Therapeutics has a 1 year low of $3.21 and a 1 year high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). As a group, equities analysts expect that Intensity Therapeutics will post -2.64 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on INTS. HC Wainwright lifted their target price on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

About Intensity Therapeutics

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors.

Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors.